Exemestane, marketed under the pharmaceutical brand name Aromasin, is a third generation steroidal aromatase inhibitor and the only mechanism based irreversible aromatase inactivator among CSD’s AI range. F40 Biotech’s formulation delivers 12.5mg per tablet in a 50 count format, half the unit dose of CSD’s 25mg generic Exemestane listing at more than double the tablet count, providing researchers with a lower unit dose and higher supply volume suited to conservative titration protocols, dose response research at the lower end of the Exemestane concentration spectrum, or extended research timelines where the 50 tablet supply at 12.5mg per dose covers a significantly longer protocol period than the 30 tablet 25mg presentation.
The 12.5mg concentration is a research relevant dose point for Exemestane specifically. Clinical literature references both 25mg daily and 12.5mg every other day administration schedules in aromatase inhibition research. The 12.5mg tablet format directly supports the every other day dosing schedule without requiring tablet splitting from a 25mg presentation, maintaining dosing accuracy across protocols where the lower frequency administration schedule is the research variable being examined. This makes the 12.5mg F40 Biotech format a practically distinct research tool from the 25mg generic format rather than simply a lower concentration version of the same product.
Exemestane’s irreversible steroidal mechanism remains consistent across both concentration presentations, androstenedione derived structure enabling permanent covalent binding to the CYP19A1 aromatase active site, irreversibly inactivating the enzyme until new aromatase protein is synthesized. This mechanism based inactivation profile distinguishes Exemestane from CSD’s non steroidal reversible inhibitors Anastrozole and Letrozole regardless of the concentration at which it is administered. The irreversibility is a property of the compound’s mechanism rather than its dose. The androgenic metabolite 17-hydroexemestane produced through Exemestane’s hepatic metabolism additionally contributes weak androgen receptor activity absent from non steroidal AI alternatives across both concentration presentations.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks Exemestane across two presentations: this F40 Biotech 12.5mg 50 tablet format and the generic brand 25mg 30 tablet format, alongside Anastrozole and Letrozole for complete comparative aromatase inhibitor research coverage from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Anastrozole and Letrozole in comparative aromatase inhibitor mechanism and estrogen suppression studies. Browse CSD’s full PCT and hormone research range for complete sourcing.
![Aromasin 12.5 mg - 50 Tablets [Anti-Estrogen]](https://www.canadasteroiddepot.is/wp-content/uploads/2024/03/aromasin-600x600.png)
![ESTRADOT 37.5 - 0.585MG - 8 PATCHES [ESTRADIOL PATCHES]](https://www.canadasteroiddepot.is/wp-content/uploads/2026/07/ESTRADAT-300x300.png)
![Aromasin 12.5 mg - 50 Tablets [Anti-Estrogen]](https://www.canadasteroiddepot.is/wp-content/uploads/2024/03/aromasin-100x100.png)